2026-01-23 - Analysis Report
**Financial Report: Johnson & Johnson (JNJ)**

**Company Overview**: Johnson & Johnson is a multinational healthcare company that operates in the fields of pharmaceuticals, medical devices, and consumer packaged goods.

**Return Rate Comparison**

| Ticker | Cumulative Return |
| --- | --- |
| JNJ (Review) | 60.51% |
| VOO (Comparison) | 92.53% |

The cumulative return of JNJ is lower than that of the S&P 500 comparison stock. The degree of divergence is a difference of -32.70%. This indicates that JNJ has underperformed compared to the S&P 500.

**Alpha, Beta Analysis**

| Period | CAGR | MDD | Alpha | Beta | Market Cap (B) |
| --- | --- | --- | --- | --- | --- |
| 2016-2018 | 6.0% | 16.8% | 2.0% | 0.7 | 310.9B |
| 2017-2019 | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020 | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021 | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022 | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024 | -30.0% | 13.8% | -49.0% | 0.2 | 348.4B |
| 2023-2025 | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

The Alpha, Beta analysis shows that JNJ has had varying returns across different periods, with some years showing significant outperformance (Alpha > 0) and others showing significant underperformance (Alpha < 0). Beta has generally remained around 0.7, indicating a stable stock with moderate volatility.

**Recent Stock Price Fluctuations**

| Metric | Value |
| --- | --- |
| Close | $218.49 |
| 5-day SMA | $218.59 |
| 20-day SMA | $210.58 |
| 60-day SMA | $203.27 |

The stock price has fluctuated, with the 5-day SMA slightly above the latest close price, indicating a short-term upward trend. However, the 20-day SMA and 60-day SMA are lower, suggesting a longer-term downtrend.

**Indicators and Analysis**

| Indicator | Value |
| --- | --- |
| RSI | 71.42 (Overbought) |
| PPO | 0.40 (Buy) |
| Expected Return | -38.60% (High Risk) |

The RSI is overbought, indicating a potential correction in the stock price. The PPO is buy, suggesting a strong upward trend. The Expected Return is -38.60%, indicating a high risk investment.

**Recent News & Significant Events**

Recent news headlines indicate mixed reactions to JNJ's Q4 earnings beat and guidance. While earnings and revenue beat expectations, the stock price declined due to concerns about Oncology drug sales.

**Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
- Opinions: 24
- Target Price (avg/high/low): 218.34 / 260.00 / 155.00

Analysts are generally bullish on JNJ, with a buy consensus and a moderate target price range.

**Recent Earnings Analysis**

| Date | EPS | Revenue |
| --- | --- | --- |
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

EPS has had fluctuations, with a high of $4.57 in Q4 2024 and a low of $1.12 in Q4 2025. Revenue has been relatively stable, ranging from $21.89B to $23.99B.

**Financial Information**

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
| --- | --- | --- |
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

Revenue has had fluctuations, with a high of $23.99B in Q3 2025. Profit margin has remained stable around 67-70%.

**Capital and Profitability**

| Quarter | Equity | ROE |
| --- | --- | --- |
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

Equity has had fluctuations, with a high of $78.47B in June 2025. ROE has ranged from 3.84% to 14.08%, indicating varying profitability across quarters.

**Comprehensive Analysis**

Based on the analysis above, JNJ has had mixed results across different periods. The stock price has fluctuated, with a short-term upward trend and a longer-term downtrend. Indicators suggest a high risk investment due to a significant expected return. Analysts are generally bullish, but the recent news headlines indicate concerns about Oncology drug sales. Financial information shows varying profitability and revenue fluctuations across quarters.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.